NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Baxter International Inc. Analyst Notes
On April 2, 2014, Baxter International Inc. (Baxter) announced that it has agreed to acquire all of Chatham Therapeutics, LLC's (Chatham) outstanding membership interests. The Company stated that it will acquire Chatham's developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia. Baxter informed that under the terms of agreement, the Company will make an initial payment of $70 million to acquire all of the outstanding membership interests of Chatham and may make additional payments in the future based on specified development, regulatory and commercial milestones. In another announcement dated, April 3, 2014, the Company stated that it will host a quarterly conference call to discuss its Q1 2014 financial results on April 17, 2014 at 7:30 a.m. CT. Baxter stated that the call will be webcast and can be accessed at the Company website. The full analyst notes on Baxter International Inc. are available to download free of charge at:
AcelRx Pharmaceuticals, Inc. Analyst Notes
On March 25, 2014, AcelRx Pharmaceuticals, Inc. (AcelRx) announced the appointment of Timothy E. Morris as the Company's CFO. AcelRx informed that Mr. Morris will be responsible for managing the Company's finance operations, information systems and human resource and investor relations functions as part of his new role. The Company stated that he succeeds Jim Welch, who had served as CFO since October 2010. According to the AcelRx, Morris holds 30 years of professional finance and accounting experience out of which 18 years of experience as CFO and prior to joining AcelRx he served as CFO at VIVUS Inc. Commenting on the appointment, Richard King, President and CEO of AcelRx, stated, "Tim's recent knowledge in transitioning a development-stage company to commercial capability in terms of finance, accounting, information systems and personnel, coupled with his experience in structuring and valuing transactions, strategic planning and executive management, make him an invaluable addition to our company." The full analyst notes on AcelRx Pharmaceuticals, Inc. are available to download free of charge at:
Synta Pharmaceuticals Corp. Analyst Notes
On April 9, 2014, Synta Pharmaceuticals Corp.'s (Synta Pharmaceuticals) stock increased 10.07%, to close at $4.48. For the past five-day trading period, the Company's shares gained 11.16% compared to the Nasdaq Composite which rose 0.98% during the same period. The full analyst notes on Synta Pharmaceuticals Corp. are available to download free of charge at:
The Spectranetics Corporation Analyst Notes
On March 27, 2014, The Spectranetics Corporation (Spectranetics) announced early success of the EXCITE ISR clinical trial, achieving highly significant statistical superiority in both safety and efficacy. According to the Company, the outcome was achieved without any borrowing from the PATENT registry. The Company informed that based on this result, Spectranetics has concluded enrollment in the EXCITE ISR trial and will submit the 510(k) application to the Food and Drug Administration (FDA) on the announcement date. Spectranetics President and CEO, Scott Drake, commented, "We are in the process of developing a new, necessary standard of care for ISR patients. Safety and efficacy superiority are the bedrock of our strategy to unlock this $750 million target market. Early success with EXCITE is another critical step toward our goal of accelerating top line growth, expanding gross margins and achieving meaningful operating leverage." Spectranetics added that In-stent restenosis (ISR) occurs when a previously placed stent becomes occluded, or blocked, and is considered to be a challenging condition to treat. The full analyst notes on The Spectranetics Corporation are available to download free of charge at:
NuVasive, Inc. Analyst Notes
On April 9, 2014, NuVasive, Inc.'s (NuVasive) stock gained 0.40%, closing at $35.46. Over the past six months of trading, NuVasive's shares advanced 43.15% compared to the Nasdaq Composite which went up by 13.75% during the same trading period. The full analyst notes on NuVasive, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review